Table 1.
Study design
| Groups | No. of animals | Vaccination | Challenge (1 × 106 TCID50) | Nasal Wash | Bleeds‐antibody determination (MN & HAI) | Bleeds Hematology/Clin Chem | ||
|---|---|---|---|---|---|---|---|---|
| Vaccine | ROA | Days | ||||||
| 1 | 8 | CLAG‐1324 (A/Indonesia/05/05, 30 μg) | IM | 0, 21 | Days 42 | Days 45 | Days 0, 21, 42, 56 (terminal samples if possible) | Days 0, 42, 45, 56 (terminal samples if possible) |
| 2 | 8 | CLAG‐1323 (A/Indonesia/05/05, 15 μg) | IM | 0, 21 | ||||
| 3 | 8 | CLAG‐1324 (A/Indonesia/05/05, 30 μg) + aluminum hydroxide adjuvant CLAG‐1073 | IM | 0, 21 | ||||
| 4 | 8 | CLAG‐1323 (A/Indonesia/05/05, 15 μg) + aluminum hydroxide adjuvant CLAG‐1073 | IM | 0, 21 | ||||
| 5 | 8 | Unvaccinated control group | IM | 0, 21 | ||||
ROA, route of administration; HAI, hemagglutination inhibition assay.